Corrigendum: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer (Annals of Oncology (2011) 22 (2582-2590) DOI: 10.1093/annonc/mdr014);Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2582-2590

  Wu, Y ^a   Amonkar, M M ^b   Sherrill, B H ^a   O'shaughnessy, J ^c   Ellis, C ^b   Baselga, J ^d   Blackwell, K L ^e   Burstein, H J ^f  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TEXAS ONCOLOGY   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Health related quality of life; HER2; Lapatinib; Metastatic; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HAZARD RATIO; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING;

EID: 82355191854     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy531     Document Type: Erratum

References (26)

1. Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002; 194: 488-501.
2. Press M, Bernstein L, Thomas P et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
3. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11: 1047-1057.
4. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
6. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
7. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
8. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
9. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
10. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
11. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
12. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as firstline therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26: 2999-3005.
13. Johnston S, Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26: 1066-1072.
14. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552.
15. Kaufman B, Trudeau M, Awada A et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009; 10: 581-588.
16. Sherrill B, Di Leo A, Amonkar MM et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin 2010; 26: 767-775.
17. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117: 577-589.
18. Sherif BN, Sherrill B, Amonkar M et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer: a quality of life analysis. Presented at the American Society of Clinical Oncology Annual Meeting (Abstr 1039) Orlando, FL 2009.
19. Burstein HJ, Blackwell K, Wu Y et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life (QOL) of patients with trastuzumabrefractory HER2+ (ErbB2+) metastatic breast cancer (MBC). ASCO Breast Cancer Symposium, Washington, DC. September 5-7, 2008 (Abstr 154) 2008.
20. Kaufman B, Wu Y, Amonkar M et al. Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer. Curr Med Res Opin 2010; 26: 1065-1073.
21. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
22. Blackwell KL, Burstein HJ, Sledge GW. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2009; 69: (24 Suppl 3) (Abstr 61). doi:10.1158/0008-5472.SABCS-09-61.
23. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-986.
24. Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898-910.
25. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
26. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-1187.